| Literature DB >> 33294077 |
Abdala Maulid Mkangala1, Huimin Liang1, Xiang-Jun Dong1, Yangbo Su1, Lu HaoHao1.
Abstract
INTRODUCTION: Isolated dissection of visceral artery organs is very infrequently reported and when it occurs it mostly affects the superior mesenteric artery (SMA) with abdominal pain as the commonest presenting symptom. However, the best therapeutic strategy in symptomatic patients has not yet been established. AIM: To evaluate the safety and efficacy of conservative, endovascular bare stent and endovascular coil assisting bare stent treatments for patients diagnosed with spontaneous isolated superior mesenteric artery dissection (SISMAD).Entities:
Keywords: abdominal pain; bare stent; coil embolization; dissection aneurysm; endovascular treatment; superior mesenteric artery dissection
Year: 2020 PMID: 33294077 PMCID: PMC7687669 DOI: 10.5114/wiitm.2020.92403
Source DB: PubMed Journal: Wideochir Inne Tech Maloinwazyjne ISSN: 1895-4588 Impact factor: 1.195
Photo 1Diagnostic abdominal CTA: A – cross-section plane shows spontaneous isolated SMA dissection with true lumen (black arrow) separated by intimal flapping (the pathognomonic finding of SISMAD) from false lumens (white arrow), B – CT reconstruction, longitudinal view revealing the entry site, dissection length and presence of pseudo-aneurysm, C – VR image lateral views revealing SMA vascular branches
Photo 2Endovascular coil assisting bare stent: A – angiography revealing the entry point of the true lumen and dissection aneurysm, B – angiography taken after bare stent deployment shows persistent dissection aneurysm, C – successful false lumen coil embolization, D – control angiography revealed good blood flow of the SMA from the proximal to the distal as well as side branches with successfully sealing of false lumen by the coil
General demographic characteristics, symptoms, angiographic findings, treatment and outcome (n = 62)
| Variables | Total ( | Conservative ( | Stenting ( | Stenting + coiling ( |
|---|---|---|---|---|
| Age | 52.55 ±7.22 | 52.64 ±5.79 | 51.84 ±8.10 | 55.44 ±4.33 |
| Sex: | ||||
| Male | 52 (83.9) | 12 (85.7) | 31 (79.5) | 9 (100) |
| Female | 10 (16.1) | 2 (14.3) | 8 (20.5) | 0 |
| Symptoms: | ||||
| Asymptomatic | 17 (27.4) | 11 (78.6) | 6 (15.4) | 0 (0) |
| Symptomatic | 45 (72.6) | 3 (21.4) | 33 (84.6) | 9 (100) |
| Duration of symptoms | 5.03 ±4.04 | 8.81 ±5.90 (1–19) | 3.97 ±2.59 | 3.89 ±1.97 |
| Abdominal pain | 45 (72.6) | 3 (21.4) | 33 (84.6 | 9 (100) |
| Nausea | 32 (51.6) | 2 (14.3) | 25 (64.1) | 5 (33.3) |
| Vomiting | 19 (30.6) | 2 (14.3) | 14 (35.9) | 3 (33.3) |
| Diarrhea | 14 (22.6) | 2 (14.3) | 8 (20.5) | 2 (22.2) |
| Blood in stool | 10 (16.1) | 0 | 6 (15.4) | 4 (44.4) |
| Risk factor: | ||||
| Hypertension | 26 (41.9) | 3 (21.4) | 19 (48.7) | 4 (44.4) |
| Atherosclerosis | 26 (41.9) | 3 (21.4) | 18 (46.2) | 4 (44.4) |
| Smoking | 16 (25.8) | 2 (14.3) | 12 (30.8) | 2 (22.2) |
| Diabetes mellitus | 0 | 0 | 0 | 0 |
| Angiographic findings: | ||||
| Type I | 11 (17.7) | 7 (50) | 4 (10.3) | 0 |
| Type IIA | 36 (58.1) | 2 (14.3) | 25 (64.1) | 9 (100) |
| Type IIB | 15 (24.2) | 5 (35.7) | 10 (25.6) | 0 |
| Dissection length [cm] | 4.72 ±1.96 | 3.60 ±1.49 | 5.09 ±2.13 | 4.86 ±1.08 |
| Distance from A-L [cm] | 2.49 ±1.06 | 2.09 ±0.77 | 2.68 ±1.19 | 2.33 ±0.52 |
| Treatment: | ||||
| Single stent | 41 (66.1) | 0 | 34 (87.2) | 7 (77.8) |
| Overlapping stent | 7 (11.3) | 0 | 5 (12.8) | 2 (22.2) |
| Diameter of stent | 7.06 ±0.56 | 0 | 7.10 ±0.59 (6–8) | 6.89 ±0.33 (6.–7) |
| Length of stent | 64.38 ±23.69 | 0 | 66.41 ±25.18 | 55.56 ±13.33 |
| Fasting days | 7.52 ±6.61 (3–28) | 17.07 ±8.51 | 5.13 ±1.30 | 4.11 ±0.60 |
| Outcome: | ||||
| Success | 58 (93.5) | 11 (79) | 38 (97.4) | 9 (100) |
| Failure | 4 (6.5) | 3 (21) | 1 (2.6) | 0 |
| Secondary treatment | 4 (6.5) | 3 (21) | 1 (2.6) | 0 |
| Follow-up | 28.76 ±12.87 | 26.50 ±12.95 | 31.46 ±13.15 | 20.56 ±6.98 |
A-L (distance from aorta to lesion entry point).
Conservative treatment group vs. endovascular bare stent treatment group (demographic characteristics, symptoms, angiographic findings, treatment and outcome)
| Variables | Conservative ( | Stenting ( | |
|---|---|---|---|
| Age | 52.64 ±5.79 | 51.84 ±8.10 | 0.737 |
| Sex: | |||
| Male | 12 (85.7) | 31 (79.5) | 0.609 |
| Female | 2 (14.3) | 8 (20.5) | |
| Clinical presentation: | |||
| Asymptomatic | 11 (78.6) | 6 (15.4) | 0.001 |
| Symptomatic | 3 (21.4) | 33 (84.6) | |
| Duration of symptoms | 8.81 ±5.90 | 3.97 ±2.59 | 0.001 |
| Abdominal pain | 3 (21.4) | 33 (84.6) | 0.001 |
| Nausea | 2 (14.3) | 25 (64.1) | 0.001 |
| Vomiting | 2 (14.3) | 14 (35.9) | 0.131 |
| Diarrhea | 2 (14.3) | 8 (20.5) | 0.609 |
| Blood in stool | 0 | 6 (15.4) | |
| Risk factor: | |||
| Hypertension | 3 (21.4) | 19 (48.7) | 0.755 |
| Atherosclerosis | 3 (21.4) | 18 (46.2) | 0.105 |
| Smoking | 2 (14.3) | 12 (30.8) | 0.230 |
| Diabetes mellitus | 0 | 0 | 0 |
| Angiographic findings: | |||
| Type I | 7 (50) | 4 (10.3) | 0.016 |
| Type IIA | 2 (14.3) | 25 (64.1) | 0.014 |
| Type IIB | 5 (35.7) | 10 (25.6) | 0.473 |
| Dissection length [cm] | 3.60 ±1.49 | 5.09 ±2.13 | 0.019 |
| Distance from A-L [cm] | 2.09 ±0.77 | 2.68 ±1.19 | 0.092 |
| Treatment: | |||
| Single stent | 0 | 34 (87.2) | |
| Overlapping stent | 0 | 5 (12.8) | |
| Diameter of stent | 0 | 7.10 ±0.59 | |
| Length of stent | 0 | 66.41 ±25.18 | |
| Fasting days | 17.07 ±8.51 | 5.13 ±1.30 | 0.0001 |
| Outcome: | |||
| Success | 11 (79) | 38 (97.4) | 0.021 |
| Failure | 3 (21) | 1 (2.6) | 0.021 |
| Secondary treatment | 3 (21) | 1 (2.6) | 0.021 |
| Follow-up | 26.50 ±12.95 | 31.46 ±13.15 | 0.229 |
P-value of < 0.05, defined as statistically significant.
A-L (distance from aorta to lesion entry point).
Endovascular bare stent treatment group vs. endovascular coil assisting bare stent treatment group (demographic characteristics, symptoms, angiographic findings, treatment and outcome)
| Variables | Stenting ( | Stenting + coiling ( | |
|---|---|---|---|
| Age | 51.84 ±8.10 | 55.44 ±4.33 | 0.206 |
| Sex: | |||
| Male | 31 (79.5) | 9 (100) | |
| Female | 8 (20.5) | 0 | |
| Clinical presentation: | |||
| Asymptomatic | 6 (15.4) | 0 (0) | |
| Symptomatic | 33 (84.6) | 9 (100) | |
| Duration of symptoms | 3.97 ±2.59 | 3.89 ±1.97 | 0.926 |
| Abdominal pain | 33 (84.6 | 9 (100) | |
| Nausea | 25 (64.1) | 5 (33.3) | 0.633 |
| Vomiting | 14 (35.9) | 3 (33.3) | 0.885 |
| Diarrhea | 8 (20.5) | 2 (22.2) | 0.909 |
| Blood in stool | 6 (15.4) | 4 (44.4) | 0.054 |
| Risk factor: | |||
| Hypertension | 19 (48.7) | 4 (44.4) | 0.817 |
| Atherosclerosis | 18 (46.2) | 4 (44.4) | 0.993 |
| Smoking | 12 (30.8) | 2 (22.2) | 0.611 |
| Diabetes mellitus | 0 | 0 | |
| Angiographic findings: | |||
| Type I | 4 (10.3) | 0 | |
| Type IIA | 25 (64.1) | 9 (100) | |
| Type IIB | 10 (25.6) | 0 | |
| Dissection length | 5.09 ±2.13 | 4.86 ±1.08 | 0.744 |
| Distance from A-L [cm] | 2.68 ±1.19 | 2.33 ±0.52 | 0.398 |
| Treatment: | |||
| Single stent | 34 (87.2) | 7 (77.8) | 0.471 |
| Overlapping stent | 5 (12.8) | 2 (22.2) | 0.471 |
| Diameter of stent | 7.10 ±0.59 | 6.89 ±0.33 | 0.308 |
| Length of stent | 66.41 ±25.18 | 55.56 ±13.33 | 0.218 |
| Procedure duration [min] | 67.54 ±7.96 | 123.33 ±5.05 | 0.001 |
| Fasting days | 5.13 ±1.30 | 4.11 ±0.60 | 0.095 |
| Outcome: | |||
| Success | 38 (97.4) | 9 (100) | |
| Failure | 1 (2.6) | 0 | |
| Secondary treatment | 1 (2.6) | 0 | |
| Follow-up | 31.46 ±13.15 | 20.56 ±6.98 | 0.021 |
P-value of < 0.05, defined as statistically significant.
A-L (distance from aorta to lesion entry point).
Conservative treatment group vs. endovascular coil assisting bare stent treatment group (demographic characteristics, symptoms, angiographic findings, treatment and outcome)
| Variables | Conservative ( | Stenting + coiling ( | |
|---|---|---|---|
| Age | 52.64 ±5.79 | 55.44 ±4.33 | 0.228 |
| Sex: | |||
| Male | 12 (85.7) | 9 (100) | |
| Female | 2 (14.3) | 0 | |
| Clinical presentation: | |||
| Asymptomatic | 11 (78.6) | 0 (0) | |
| Symptomatic | 3 (21.4) | 9 (100) | |
| Duration of symptoms | 8.81 ±5.90 | 3.89 ±1.97 | 0.030 |
| Abdominal pain | 3 (21.4) | 9 (100) | |
| Nausea | 2 (14.3) | 5 (33.3) | 0.073 |
| Vomiting | 2 (14.3) | 3 (33.3) | 0.279 |
| Diarrhea | 2 (14.3) | 2 (22.2) | 0.624 |
| Blood in stool | 0 | 4 (44.4) | |
| Risk factor: | |||
| Hypertension | 3 (21.4) | 4 (44.4) | 0.242 |
| Atherosclerosis | 3 (21.4) | 4 (44.4) | 0.245 |
| Smoking | 2 (14.3) | 2 (22.2) | 0.624 |
| Diabetes mellitus | 0 | 0 | 0 |
| Angiographic findings | |||
| Type I | 7 (50) | 0 | |
| Type IIA | 2 (14.3) | 9 (100) | |
| Type IIB | 5 (35.7) | 0 | |
| Dissection length | 3.60 ±1.49 | 4.86 ±1.08 | 0.040 |
| Distance from A-L [cm] | 2.09 ±0.77 | 2.33 ±0.52 | 0.421 |
| Treatment: | |||
| Single stent | 0 | 7 (77.8) | |
| Overlapping stent | 0 | 2 (22.2) | |
| Diameter of stent | 0 | 6.89 ±0.33 | |
| Length of stent | 0 | 55.56 ±13.33 | |
| Fasting days | 17.07 ±8.51 | 4.11 ±0.60 | 0.0001 |
| Outcome: | |||
| Success | 11 (79) | 9 (100) | |
| Failure | 3 (21) | 0 | |
| Secondary treatment | 3 (21) | 0 | |
| Follow-up | 26.50 ±12.95 | 20.56 ±6.98 | 0.222 |
P-value of < 0.05, defined as statistically significant.
A-L (distance from aorta to lesion entry point).
Photo 3Management of bare stent stenosis by secondary stenting: A – angiography shows filling defect in the lumen of a bare stent at the proximal part indicating stenosis of the stent lumen, B – deployment of a secondary stent, C – secondary stent successfully deployed at the lesion site, D – control angiography revealing disappearance of filling defects after secondary stenting